Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Developed in consultation with clinicians and patients for an enhanced user experience
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
Krsnaa Diagnostics receives LoI from RINPAS for radiology services
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Total investment incurred for setting up the new R&D Rs 250 crore
Subscribe To Our Newsletter & Stay Updated
